COMPARATIVE STUDIES WITH DIFFERENT CYCLODEXTRIN DERIVATIVES IN IMPROVING THE SOLUBILITY AND DISSOLUTION OF SAQUINAVIR by Sogali, Bharani S et al.
Vol 11, Issue 6, 2018
Online - 2455-3891 
Print - 0974-2441
COMPARATIVE STUDIES WITH DIFFERENT CYCLODEXTRIN DERIVATIVES IN IMPROVING 
THE SOLUBILITY AND DISSOLUTION OF SAQUINAVIR
BHARANI S SOGALI1*, VIKRAM BN1, RAMANA MURTHY KV2
1Department of Pharmaceutics, Krupanidhi College of Pharmacy, Bengaluru – 560 035, Karnataka, India. 2Department of Pharmaceutics, 
Andhra University, Visakhapatnam, Andhra Pradesh, India. Email: bssogali@gmail.com
Received: 18 January 2018, Revised and Accepted: 16 February 2018
ABSTRACT
Objective: The present study was aimed to perform comparative studies with different cyclodextrin (CD) derivatives and to study the effect of 
different methods of preparation in improving the solubility and dissolution of saquinavir (SQV).
Methods: Phase solubility studies were performed with beta CD (βCD), hydroxypropyl βCD, randomly methylated βCD, and sulfobutyl ether βCD 
(SBE7βCD). Complexes were prepared using physical mixture, coevaporation, kneading, spray drying, and freeze-drying techniques. For complexes 
prepared by spray drying, process parameters were optimized based on percentage yield. The prepared complexes were characterized using Fourier-
transform infrared spectroscopy, differential scanning calorimetry, X-ray diffraction studies, nuclear magnetic resonance spectroscopy, and scanning 
electron microscopy. In vitro drug release study was conducted in phosphate buffer pH 6.8 and mean dissolution time (MDT) was calculated for all 
freeze-dried complexes.
Results: Phase solubility studies showed a linear relationship with an increase in CD concentration and phase diagrams were of AL type. Highest 
stability constant was observed with SQV-SBE7βCD (8281.28/M). All characterization studies proved complexation. Among four CD derivatives, SQV 
complexed with SBE7βCD by freeze-drying showed maximum drug release and low MDT of 20.67.
Conclusion: Among different CDs, SBE7βCD proved as ideal CD derivative, and among different methods of preparations, freeze-drying method was 
found to be useful in improving the solubility and dissolution of SQV.
Keywords: Saquinavir, Cyclodextrin, Complexation, Freeze drying, Sulfobutyl ether beta cyclodextrin.
INTRODUCTION
The improvement of oral bioavailability of poorly water-soluble 
drugs remains one of the most challenging aspects of drug 
development. Although there are many approaches available for 
improving dissolution rate and oral bioavailability, each method is 
having its own limitations. Complexation with cyclodextrins (CDs) is 
one of the widely used techniques for the enhancement of dissolution 
rate. Drug-CD complexation and improvement in solubility and 
dissolution rate are influenced by both nature of the CD (native or 
chemically modified, crystalline, or amorphous) and the method of 
complexation, namely, cogrinding, kneading, solid dispersion, solvent 
evaporation, coprecipitation, spray drying, or freeze drying [1-3]. 
The effectiveness of a method depends on nature of the drug and 
CD [4-7]. In many cases, spray drying and freeze drying were found 
to be more effective in improving the dissolution of poorly soluble 
drugs [8-12].
In the present research work, poorly soluble HIV-protease inhibitor, 
saquinavir (SQV) (BCS Class II drug) was selected which has poor 
water solubility and is reported to be an excellent P-gp and CYP3A 
substrate [13,14]. The oral bioavailability has been reported to be very 
low (0.7–4.0%), and it is dependent on the dosage form used. SQV 
has been available as hard gelatin capsules, containing SQV mesylate 
(200 mg strength as SQV free base) [15]. Typically, it is dosed 2 times 
daily as five 200 mg capsules in combination with ritonavir (100 mg 
twice daily). It is recommended that it should be taken with meals.
Although many earlier studies on CDs were reported for the 
enhancement of solubility and dissolution rate, very few comparative 
studies were reported [16,17]. Hence, in the present investigation, 
an attempt was made to compare the applicability of different CD 
derivatives, beta CD (βCD), hydroxypropyl βCD (HPβCD), randomly 
methylated βCD (RMβCD), and sulfobutyl ether βCD (SBE7βCD) and 
influence of different methods of preparation in the development of 
complexes for improving dissolution.
MATERIALS AND METHODS
Materials
SQV was kindly purchased from Hetero Chemicals, Hyderabad, India. 
βCD was gifted from Signet Pharma, India. HPβCD and RMβCD were 
gift samples received from Roquette Pharma, Italy. SBE7βCD was kindly 




Phase solubility studies were performed as mentioned by Higuchi and 
Connors, 1965 [18] in pH 6.8 phosphate buffer to determine suitable 
CD derivative in solubility enhancement. Solubility studies were carried 
out by adding excess amounts of drug separately in quantities exceeding 
its aqueous solubility to 50 mL of buffer, containing increasing 
concentrations of CDs (2–12 mM). The resulting suspensions were 
shaken at room temperature for 72 h until equilibrium was established. 
The samples were filtered through a 0.45 µm membrane filter (Millex-
HA filter units, Millipore) and suitably diluted with pH 6.8 phosphate 
buffer before analysis. All studies were performed in triplicate.
Apparent 1:1 stability constants were calculated from the straight-line 
portion of the phase solubility diagrams, according to the Equation 1.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Where So is the solubility of the drug in examined buffer solution in the 
absence of ligand.
Preparation of drug-CD complexes [8,19-21]
In the present work, drug-CD complexes were prepared using physical 
mixing, coevaporation, kneading, spray drying, and freeze drying.
Physical mixing
Drug and CDs at equimolar ratio (1:1) were weighed and mixed in a 
mortar by geometric dilution method for sufficient time (~5 min) to 
obtain a homogenous powder blend, passed through sieve no. 80, and 
stored in a sealed glass vials and kept in desiccator over fused calcium 
chloride until further use.
Kneading
CDs were wetted in a mortar with a minimum volume of water:ethanol 
mixture (1:1) until a paste was obtained. The required amount of drug 
was slowly added, and the slurry was kneaded for about 45 min. During 
this process, a suitable quantity of solvent was added to maintain 
optimum consistency. Further, the products were dried at 40°C to 
constant weight, passed through sieve no. 80, and stored in a desiccator 
until further evaluation.
Solvent evaporation
Required quantities of drug and CD were dissolved in sufficient quantity 
of water:ethanol solvent mixture (1:1) and evaporated on a water bath 
at 50°C with stirring. Each solid product was sieved through #80 and 
stored in a desiccator.
Spray drying [22-24]
In spray drying, characteristic properties of powders such as particle 
size and shape obtained are influenced by the nozzle, the viscosity 
of the feeding solution, and the outlet temperature (Tout), and the 
latter being dependent on the two spray drying process variables: 
Inlet temperature (Tin) and solution flow. To select best optimizing 
conditions, SQV with βCD combination was used and the same process 
conditions were applied with other CDs used in complex formation. For 
optimization, the influence of solution flow rate and Tin was studied, and 
the solutions were atomized at three different flow rates (2, 5. and 10 
ml/min) using fixed values for compressed air (500 l/h) and aspirator 
(40 m3/h). Two Tin values were used: 55°C and 70°C. Tout was kept 
constant at a temperature of 50°C.
Spray drying was performed using Labultima LU22 spray dryer for 
the preparation of inclusion complexes. Equimolar ratio of drug and 
CDs was dissolved in sufficient quantity of ethanol and water mixture 
(1:1). The solutions were atomized at a flow rate 2 ml/min using fixed 
values for compressed air (500 L/h) and aspirator 40–50 m3/h with Tin 
value of 70°C, corresponding to a Tout of 48°C. After spray drying, each 
resulting powder was collected by cyclone separation and transferred 
to glass vials. After spray drying, all complexes were kept in an oven at 
40°C for 24 h to remove traces of moisture present in the complexes.
Freeze drying/lyophilization
Required quantity of CD was dissolved in sufficient quantity of water, 
and required quantity of drug was added and dispersed. The dispersion 
was kept under magnetic stirring at 200 rpm for 72 h in closed vials for 
complex formation which resulted in the formation of a clear solution. 
The resulting solution was fast frozen at −20°C using liquid nitrogen 
and dried at −50°C and 0.0070 mbar pressure in a freeze dryer (Model 
MODUL YOD 230, Thermo Electron Corporation, India) for 48 h. The 
obtained freeze-dried product in the glass vial was stored in a desiccator.
Determination of moisture content
The residual moisture content of the spray-dried complexes was 
determined through loss on drying using a HR83 halogen moisture 
analyzer (Mettler-Toledo, India). A sample of 0.5 g was dried at 105°C 
for 5 min.
In vitro release characteristics of complexes
Dissolution experiments were carried out in triplicate (n=3) with an 
USP XXIII paddle apparatus in 900 ml of pH 6.8 phosphate buffer at 
37°C using a rotation speed of 50 rpm. In each study, drug-CD complex 
equivalent to 100 mg of drug was used. 5 ml sample was withdrawn at 
intervals of 5, 15, 30, 45, and 60 min using a syringe fitted with prefilter 
(0.45 µm). An equal amount of fresh dissolution medium maintained at 
the same temperature was replaced immediately after withdrawal of 
the test sample. Test samples were suitably diluted wherever necessary, 
and the absorbance was measured as per the analytical procedures 
described. The mean percentage of drug dissolved and the standard 
deviations (SD) were calculated.
Drug-excipient interaction studies
Drug-excipient interaction studies were conducted for SQV, pure CDs, 
physical mixtures, and freeze-dried complexes to gain insight into 
interactions between drug and respective CDs in the complexed form.
Fourier-transform infrared (FTIR) spectroscopy
FTIR spectra were used to identify the formation of complex. 
Samples were analyzed by potassium bromide pellet method in an IR 
spectrophotometer (Shimadzu, FTIR 1300) in the region between 400 
and 4000/cm. Complex formation was evaluated by comparing the 
IR spectra of the solid complex with drug. For comparison purposes, 
FTIR spectra were obtained for SQV, each βCD being studied as well as 
physical mixtures of both drugs with each CD.
Differential scanning calorimetry (DSC)
The thermal behavior of SQV and CD inclusion complexes was studied 
using DSC to confirm the formation of solid complex. When guest 
molecules are incorporated in the CD cavity or in the crystal lattice, 
their melting, boiling, and sublimation points are usually shifted to a 
different temperatures or disappear within the temperature range. The 
samples were heated from 0°C to 350°C at a heating rate of 10°C/min 
under a nitrogen flow and flowing at a rate of 40 mL/min through the 
DSC cell.
Powder X-ray diffraction (PXRD) study
XRD of inclusion complexes and the pure drug were performed to 
identify the interaction of the drug with CDs using a PW 1720 X-ray 
generator and a PW 1710 diffractometer control (Philips Electronic 
Instrument). The scanning range (2θ) was from 5° to 90°, and the scan 
step and scan speed were 0.04° and 0.02°/s, respectively.
Nuclear magnetic resonance (NMR) spectroscopy
1H-NMR studies were conducted to determine the electronic 
interactions between drug and CDs  and it was studied using Bruker 
AM400 spectrophotometer. Samples were prepared by dissolution of 
the drug in methanol as a solvent for RTV. 1H-NMR spectra of inclusion 
complexes and pure components were recorded. Chemical shifts 
were reported in ppm (δ) downfield from tetramethylsilane (internal 
reference).
Scanning electron microscopy (SEM)
The morphological properties of the SQV, physical mixture, and freeze-
dried powders of SQV-SBE7βCD complex were characterized by scanning 
electronic microscopy (Cambridge instrument: Stereoscan 360).
RESULTS AND DISCUSSION
Phase solubility studies
The solubility of SQV increased linearly as a function of CD 
concentration. The phase solubility profiles showed a linear increase in 
complexation of SQV with an increase in CD concentration with all four 
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CDs, displaying type AL phase diagrams according to the classification 
by Higuchi. The correlation coefficient of the linear regression line for 
each of the phase solubility curves was >0.99, indicating a good fit for 
all complexes.
The slope of the lines was found to be 0.2855 for βCD, 0.5954 for 
HPβCD, 0.7711 for RMβCD, and 0.7762 for SBE7βCD. As the slope of the 
line is less than unity, it was assumed that the increase in the solubility 
observed was due to the formation of a 1:1 molar complex.
The stability constants (K1:1) of SQV with each CD were calculated using 
Equation 1 and given in Table 1. The calculated values were 906.6/M 
for βCD, 3706.2/M for HPβCD, 6899.46/M for RMβCD, and 8281.28/M 
for SBE7βCD. The K1:1 value for SQV -SBE7βCD complex was found to 
be 8281.28/M which is 9-fold higher than βCD, 2.23-fold higher than 
HPβCD, and 1.2-fold higher than RMβCD, indicating that SBE7βCD has 
superior SQV complexing efficiency. This may potentially be due to SQV 
interacting with the anionically charged moiety of the SBE7βCD.
In the present study, the enhancement of SQV solubility was highly 
dependent on the type of CD used. Based on the phase solubility 
diagrams, SBE7βCD is more effective in solubilizing SQV in pH 6.8 
phosphate buffer compared to other CDs. The order of solubilizing 
capacity of CDs was as follows: SBE7βCD>RMβCD>HPβCD>βCD. The 
different complexation constants found for different CD molecules 
indicated that the derivative groups on CDs appear to play an important 
role in the incorporation of SQV into CD cavity since much higher 
complexation constants were obtained with RMβCD and SBE7βCD.
Preparation of drug-CD complexes
The phase solubility studies carried out with different CDs on both 
drugs indicated the formation of complex in 1:1 molar ratio. Drug-CD 
complexes were prepared with all the four CDs for SQV, whereas HPβCD 
and RMβCD were used for ritonavir using four different methods of 
preparation. In each method, 4–5 g of drug-CD complexes was prepared 
at equimolar ratio.
Study of spray drying process conditions
The result of the determination of the yield for each one of the 
experimental conditions is shown in Table 2. The yield obtained under 
varying conditions of Tin and flow rate was in the range of 37–62%. 
Yield was significantly influenced by flow rate rather than Tin in which 
lower flow rate resulted in higher yield. No significant difference in 
yield was observed between the two Tin values. Earlier reports also 
confirmed this result in which higher flow rates resulted in low yields in 
the range of 40–50% [25-27]. These low yield values could be justified 
by the biggest number of atomized particles that adhere more to the 
walls of the drying chamber and its removal for the cyclone collector 
being more difficult.
Hence, a flow rate of 2 ml/min with a Tin of 55°C was found to be 
optimized conditions which gave the highest yield of 62% drug-CD 
complexes and these two conditions were used for the preparation of 
drug-CD complexes by spray drying technique.
Determination of moisture content
Moisture content for all the complexes was in the range of 0.9–2.5% 
(Table 3) SQV complex prepared with SBE7βCD showed slightly higher 
moisture content compared to other CDs. Earlier reports also indicated 
higher moisture content for complexes prepared with SBE7βCD due to 
its hygroscopic nature [28].
Dissolution studies of SQV-CD complexes
Dissolution characterizes of a dosage form have a direct bearing on its 
efficacy, especially when the medicament is poorly soluble or insoluble 
in aqueous fluids. In general, for poorly soluble drugs, difficulties are 
usually encountered in selecting a suitable dissolution medium with 
good discriminating power. Dissolution of drugs from solid dosage form 
is a key parameter in assessing the release rate, release mechanism, and 
kinetics at product development stage. SQV capsules and tablets are 
official in IP and USP. Citrate buffer (pH 3.0) is mentioned as dissolution 
medium in all official books and the FDA listed drugs [29,30]. However, 
this medium is not suitable as discriminating medium as SQV is highly 
soluble in this media as per studies conducted by Pathak et al. [31] Hence, 
pH of the dissolution media was selected based on discriminating ability, 
and pH of upper gastrointestinal for SQV, i.e., pH 6.8 phosphate buffer.
All dissolution studies were performed for 60 min as the objective of 
the present investigation was to achieve the complete drug release 
within this period. Drug-CD complexes failing to achieve this objective 
were not studied further. Drug-CD complex equivalent to 100 mg of the 
drug was used for dissolution study in each case, and each study was 
replicated for 3 times and average values with SD are reported in tables.
From the dissolution studies, it was observed that only 20.82% 
dissolution of pure SQV was observed in 60 min. The dissolution of SQV 
with βCD, HPβCD, RMβCD, and SBE7βCD physical mixtures showed a 
release of 27.21–38.44% of SQV. Complexes prepared by kneading 
method showed drug release of 36.57–47.29% and that are prepared 
with coevaporation method showed 37.6–48.05% with all the four 
CDs. Among different methods of preparation, spray-dried (37.75–
80.63%) and freeze-dried (38.74–99.27%) complexes showed higher 
drug release in 60 min of dissolution study. Among all complexes, 
SQV-SBE7βCD complexes prepared by freeze-drying method showed 
complete drug release within the stipulated time.
All inclusion complexes showed improvement of drug release compared 
to SQV alone except for physical mixtures where the enhancement is 
negligible. Complexes prepared by spray drying and freeze-drying 
methods showed marked enhancement in dissolution compared to 
other methods for all CDs. The order of drug release from complexes 
prepared by different methods was FD>SD>COE>KN>PM for βCD and 
HPβCD. This may be due to the heat used in coevaporation which helps 
in complex formation. In case of RMβCD and SBE7βCD, kneading method 
Table 1: Stability constants of SQV with four CDs
Type of CD K1:1/M Phase diagram
βCD 906.80 AL type
HPβCD 3706.20 AL type
RMβCD 6899.46 AL type
SBE7βCD 8281.28 AL type
SQV: Saquinavir, CDs: Cyclodextrins, βCD: Beta cyclodextrin, 
HPβCD: Hydroxypropyl beta cyclodextrin, RMβCD: Randomly methylated beta 












SQV: Saquinavir, βCD: Beta cyclodextrin
Table 3: Moisture content of spray-dried complexes





*SD: Standard deviation. SQV: Saquinavir, CD: Cyclodextrin, βCD: Beta 
cyclodextrin, HPβCD: Hydroxypropyl beta cyclodextrin, RMβCD: Randomly 
methylated beta cyclodextrin, SBE7βCD: Sulfobutyl ether beta cyclodextrin
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showed higher drug release than coevaporation. When the effect of 
type of CD was observed, complexes prepared with SBE7βCD showed 
good enhancement in dissolution. The improvement in dissolution 
follows the order: SBE7βCD>RMβCD>HPβCD>βCD. Enhanced drug 
release with SBE7βCD could be attributed to its charged groups which 
are appropriately spaced from the cavity and also increased in the 
hydrophobicity around the cavity due to the presence of alkyl chains.
DE10 and T50 were calculated only for spray-dried and freeze-dried 
products as the drug release was very slow for other methods, physical 
mixing, kneading, and coevaporation, and some of the complexes did 
not show even 50% of drug release. All drug-CD complexes showed 
higher %DE60 and DP30 values compared to pure drug. Among different 
CDs used in the study, complexes prepared with SBE7βCD showed 
higher %DE60 and DP30. When the method of preparation was observed, 
freeze-dried and spray-dried products exhibited higher % DE60 and 
DP30 values than the physical mixture, kneaded and coevaporated 
products, and SQV. Kneaded products showed higher %DE60 and DP30 
compared to coevaporated products with SQV-RMβCD and SBE7βCD. 
On the contrary, coevaporated products showed higher %DE60 and DP30 
than kneaded products with βCD and HPβCD complexes. Higher %DE10 
and lower T50 values were observed with spray-dried and freeze-dried 
complexes prepared with SBE7βCD. The extent of the enhancement of 
the dissolution was found to be dependent on the preparation method 
and the type of CD since SQV-SBE7βCD complex prepared by freeze 
drying exhibited 4.14-fold higher DE60 value and two-fold increase in DP30 
values compared to pure SQV.
Mean dissolution time (MDT) values were calculated for freeze-
dried complexes as they gave maximum drug release. All freeze-
dried complexes showed a decrease in MDT compared to SQV alone. 
The lowest MDT was observed with complexes prepared by freeze 
drying with SBE7βCD (Fig. 1). The lower the MDT value, the faster 
the drug release. Very high MDT was found for SQV, 238.01 where as 
SQV- SBE7βCD complex  gave very low MDT of 20.67 indicated the 
inclusion of SQV with SBE7βCD by freeze-drying method enhanced 
the dissolution rate. The enhancement with freeze-dried complexes 
may be due to increased interaction and conversion of drug into highly 
amorphous state in freeze-drying method.
Drug-excipient interaction studies
FTIR studies
FTIR studies of SQV exhibited peaks at 3529/cm for OH stretching, 
3100/cm for NH2 stretching, 1622/cm for C=O stretching, and 3381/ cm 
for NH stretching which confirms the structure of SQV. The spectra of 
RMβCD showed prominent peaks at 3400.02/cm for O-H stretch and 
2923.07/cm for C-H aliphatic stretch. IR spectra of physical mixture of 
SQV-RMβCD showed broadening of the peak from 3150 to 3500/ cm 
and increase in the intensity of C-H aliphatic stretch at 2935.76/
cmindicates an interaction between SQV and RMβCD.
The spectra of SBE7βCD showed prominent peaks at 3425/cm for O-H 
stretch, 2936.7/cm for C-H stretch, and 1647.2/cm for C=O stretch. The 
peaks of physical mixture of SBE7βCD were smoothened compared to 
that of SQV indicating complexation between SQV and SBE7βCD. FTIR 
spectrum of SQV-SBE7βCD freeze-dried complex shows characteristic 
broad peak at 3291.89/cm (Fig. 2). This shift and broadening of peak 
indicated complexation between SQV and SBE7βCD.
The FTIR spectrums of complexes showed a substantial decrease in 
intensity and broadening compared to that of SQV. This result suggested 
the formation of a new supramolecular compound. In addition, no 
new peaks were observed in the spectra of SQV-CD complex systems, 
indicated that no new chemical compounds were created in the 
complex formation. Thus, the FTIR spectra indicated that SQV is 
partially included into the CD to form inclusion complex.
DSC studies
The DSC thermogram of SQV showed an endothermic peak at 239°C 
which was corresponding to its melting point. The DSC spectra of RMβCD 
showed a broad endothermic peak in the range of 80–100°C which can 
be attributed to desolvation. The physical mixture of SQV and RMβCD 
showed an endothermic peak at 233°C and freeze-dried complex showed 
broadening of endothermic peak in the range 226–260°C, respectively, 
due to the formation of inclusion complex. The DSC thermogram for 
SBE7βCD showed at 270°C, whereas the physical mixture of SQV and 
SBE7βCD showed very less intense peak which indicated good interaction 
happened in physical mixing itself with SBE7βCD (Fig. 3). Freeze-dried 
complex showed reduced intensity of endothermic peak and shifted to 
237.05°C due to the carrier induced drug amorphous conversion.
NMR spectroscopy
Only1H-NMR spectroscopy can afford the most direct evidence for a 
true inclusion complex formation by evidencing interactions between 
guest molecules and the host CDs. All the proton signals in the 1 H-NMR 
spectrum of the pure SQV were observed at 1.26 ppm which represents 
aliphatic amine, at 6.7–6.9 ppm which represents  multiplet aromatic 
protons and other prominent chemical shifts were observed at 2.76 and 
4.7 ppm. Proton signals for benzene rings in SQV were represented δH 
at 6.7 ppm, 6.9 ppm, 7.1 ppm, 7.75 ppm, 7.9 ppm, 8.05 ppm, 8.1 ppm, 
8.14 ppm, and 8.5 ppm. 42δH at 4.7 ppm represented the signal of water 
(Fig. 4).
The insertion of SQV molecule into CD cavity was demonstrated by 
changes in 1H-NMR chemical shift values. NMR spectra clearly indicated 
interactions between SQV and H-3 and H-5 protons belonging to the 
host CD and pointed toward the interior of the cavity. Significant 
changes were observed in the signal due to H-3 and H-5, whereas H-1, 
H-2, H-4, and H-6 (located outside the cavity) were relatively unshielded 
by SQV. The shifts observed for the CD protons were indicative of the 
occurrence of an inclusion of SQV into the CD cavity. In case of SQV, 
a significant upfield shift for the resonance of the protons of the two 
aromatic cycles of SQV (isoquinoline ring and phenyl ring) was observed 
in the presence of CD. This upfield shift noted for the resonance of 
aromatic protons indicated that the two aromatic cycles of SQV were 
mainly involved in the formation of the complex, suggesting that both 
isoquinoline and phenyl ring moieties would be expected to be included 
with in CD cavity due to their hydrophobicity and satisfactory geometry. 
The study clearly showed a significant reduction in signal intensity with 
SQV-SBE7βCD complex and shifting of peaks indicating SQV completely 
included with SBE7βCD than with other CDs.
XRD studies
In the X-ray diffractogram of SQV, sharp peaks at a diffraction angle (2θ) 
of 12°, 16°, 17°, 18°, 19°, and 20° were present which suggested that 
Fig. 1: Bar diagram of mean dissolution time values for 
saquinavir-cyclodextrin complexes prepared by freeze-drying 
method
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the drug is present as a crystalline material (Fig. 5). In the freeze-dried 
complexes prepared with RMβCD and SBE7βCD, the presence of free 
crystalline drug was revealed by few sharp peaks of low intensity at 
21°, which emerged on the diffuse background due to the amorphous 
CDs, indicating loss of crystallinity in the drug and due to reduction of 
size of particles during the process of freeze drying which indicated the 
formation of inclusion complex. It was observed that the intensity of 
crystalline peaks of freeze-dried complex of SQV-SBE7βCD was reduced 
to a greater extent compared to other CD derivatives. This may be due to 
the better interaction between the drug and SBE7βCD which converted 
the drug into amorphous form.
SEM
The SEM of SQV and SQV-SBE7βCD complexes prepared by spray drying 
and freeze drying is shown in Fig. 6. SQV has appeared as irregular 
shaped crystals and was constituted by relatively bulky particles, with 
smaller ones adhered on its surface. Spray-dried samples appeared with 
uniform spherical-shaped particles, and freeze-dried samples appeared 
as elongated particles. The drastic change of the particle’s shape and 
aspect in the spray-dried and freeze-dried samples was indicative of the 
presence of a single phase, thus correlating with PXRD observations.
CONCLUSION
Comparative studies of SQV-CD complexes with different CDs such as 
βCD, HPβCD, RMβCD, and SBE7βCD for improving the bioavailability 
of BCS Class II drug and SQV were carried out. Simultaneously, 
the influence of the method of preparation and finding out best 
CD derivative in improving solubility and dissolution of SQV were 
studied. With the help of phase solubility studies, quantities of CDs 
were minimized in the preparation of drug-CD complexes. Formation 
of inclusion complexes was established with the help of FTIR, DSC, 
1H-NMR, XRD, and SEM studies. Among different CDs, SBE7βCD proved 
as best CD derivative in forming complex with SQV, and among different 
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useful in improving the solubility and dissolution. Further studies on 
optimized complex form of SQV may lead to reduction of the dose of 
SQV due to improved bioavailability.
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